Lobular Neoplasia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LBL001 MIFTS: 50	Lobular Neoplasia Categories: Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Lobular Neoplasia

MalaCards integrated aliases for Lobular Neoplasia:

Name: Lobular Neoplasia ¹² ¹⁵ ⁷⁴

Lobular Carcinoma in Situ of Breast ⁷⁴

Non-Infiltrating Lobular Carcinoma ⁷⁴

Lobular Intraepithelial Neoplasia ¹²

Lobular Carcinoma in Situ ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

In situ neoplasms

Carcinoma in situ of breast

Lobular carcinoma in situ

External Ids:

Disease Ontology ¹² DOID:3010

NCIt ⁵¹ C27939

ICD10 ³⁴ D05.0

UMLS ⁷⁴ C0279563 C0334381 C0861352

Sources

Summaries for Lobular Neoplasia

Disease Ontology : ¹² A breast carcinoma in situ that is characterized by abnormal cells are found in the lobules (glands that make milk) of the breast.

MalaCards based summary : Lobular Neoplasia, also known as lobular carcinoma in situ of breast, is related to in situ carcinoma and ductal carcinoma in situ. An important gene associated with Lobular Neoplasia is CDH1 (Cadherin 1), and among its related pathways/superpathways are ERK Signaling and Nanog in Mammalian ESC Pluripotency. The drugs Docetaxel and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include breast and bone, and related phenotypes are Decreased cell migration and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Wikipedia : ⁷⁷ Lobular neoplasia can refer... more...

Sources

Related Diseases for Lobular Neoplasia

Diseases related to Lobular Neoplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 99)

#	Related Disease	Score	Top Affiliating Genes
1	in situ carcinoma	30.5	CDH1 ERBB2 ESR1
2	ductal carcinoma in situ	29.7	CDH1 ERBB2 ESR1 MUC1
3	breast disease	29.4	ERBB2 ESR1 ESR2 PRLR
4	breast cancer	28.4	CDH1 CTNNB1 ERBB2 ESR1 ESR2 MUC1
5	vaginitis	10.4	ESR1 ESR2
6	large intestine adenocarcinoma	10.3	CDH1 CTNNB1
7	progesterone resistance	10.3	ESR1 ESR2
8	goblet cell carcinoid	10.3	CDH1 CTNNB1
9	gender identity disorder	10.3	ESR1 ESR2
10	breast fibroadenoma	10.3
11	estrogen excess	10.3	ESR1 ESR2
12	dental fluorosis	10.3	ESR1 ESR2
13	female reproductive endometrioid cancer	10.3	CTNNB1 ESR1
14	endometriosis of ovary	10.3	ESR1 ESR2
15	benign breast phyllodes tumor	10.2
16	gastric diffuse adenocarcinoma	10.2	CDH1 CTNNA1
17	tongue disease	10.2	CDH1 CTNNB1
18	biphasic synovial sarcoma	10.2	CDH1 MUC1
19	endometrial mucinous adenocarcinoma	10.1	ESR1 MUC1
20	colonic disease	10.1	CDH1 CTNNB1 ESR1
21	sarcomatoid renal cell carcinoma	10.1	CDH1 MUC1
22	male reproductive organ cancer	10.1	CDH1 CTNNB1 ESR2
23	syringoma	10.1	ESR1 MUC1
24	postmenopausal atrophic vaginitis	10.1	ESR1 ESR2 PRLR
25	lymphoepithelioma-like carcinoma	10.1	CDH1 MUC1
26	adenomyoma	10.1	CTNNB1 MUC1
27	colon adenocarcinoma	10.1	CDH1 CTNNB1 ESR2
28	tongue cancer	10.1	CDH1 CTNNB1 PRLR
29	chondroid chordoma	10.1	CDH1 MUC1
30	sulfite oxidase deficiency due to molybdenum cofactor deficiency	10.1
31	gastric cardia carcinoma	10.1	CDH1 MUC1
32	peritoneal mesothelioma	10.1	ESR1 MUC1
33	sclerosing hemangioma	10.1	CTNNB1 MUC1
34	breast cystic hypersecretory carcinoma	10.1	CDH1 ERBB2
35	glassy cell carcinoma of the cervix	10.1	ERBB2 ESR1
36	breast medullary carcinoma	10.0	ERBB2 ESR1
37	comedo carcinoma	10.0	ERBB2 ESR1
38	breast adenoid cystic carcinoma	10.0	ERBB2 ESR1
39	signet ring cell adenocarcinoma	10.0	CDH1 MUC1
40	diffuse gastric cancer	10.0	CDH1 CTNNA1
41	polymorphous low-grade adenocarcinoma	10.0	CTNNB1 MUC1
42	epstein-barr virus-associated gastric carcinoma	10.0	CDH1 CTNNB1
43	luminal breast carcinoma	10.0	ERBB2 ESR1
44	breast benign neoplasm	10.0	ERBB2 ESR1
45	thoracic benign neoplasm	10.0	ERBB2 ESR1
46	uterine corpus cancer	10.0	ERBB2 ESR1
47	sarcoma, synovial	10.0	CDH1 CTNNB1 MUC1
48	intrahepatic cholangiocarcinoma	10.0	CDH1 CTNNB1 MUC1
49	hidradenocarcinoma	9.9	ERBB2 ESR1
50	bile duct adenocarcinoma	9.9	CDH1 MUC1

Graphical network of the top 20 diseases related to Lobular Neoplasia:

Sources

Symptoms & Phenotypes for Lobular Neoplasia

GenomeRNAi Phenotypes related to Lobular Neoplasia according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased cell migration	GR00055-A-1	9.26	CASK CTNNA1 CTNNB1 MUC1
2	Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance	GR00210-A	8.92	CTNNA1 CTNNB1 ERBB2 MUC1

MGI Mouse Phenotypes related to Lobular Neoplasia:

⁴⁷ (show all 15)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.19	CASK CDH1 CTNNA1 CTNNB1 ERBB2 ESR1
2	growth/size/body region	MP:0005378	10.11	CASK CDH1 CTNNA1 CTNNB1 ERBB2 ESR1
3	behavior/neurological	MP:0005386	10.09	CASK CTNNB1 ERBB2 ESR1 ESR2 HSP90AA1
4	endocrine/exocrine gland	MP:0005379	10.08	CDH1 CTNNA1 CTNNB1 ERBB2 ESR1 ESR2
5	integument	MP:0010771	10.03	CASK CDH1 CTNNA1 CTNNB1 ERBB2 ESR1
6	digestive/alimentary	MP:0005381	9.99	CASK CDH1 CTNNB1 ERBB2 ESR1 ESR2
7	embryo	MP:0005380	9.97	CDH1 CTNNA1 CTNNB1 ERBB2 ESR1 PRLR
8	mortality/aging	MP:0010768	9.97	CASK CDH1 CTNNA1 CTNNB1 ERBB2 ESR1
9	limbs/digits/tail	MP:0005371	9.95	CASK CTNNA1 CTNNB1 ERBB2 ESR1 ESR2
10	craniofacial	MP:0005382	9.92	CASK CTNNA1 CTNNB1 ERBB2 HSP90AA1
11	neoplasm	MP:0002006	9.87	CDH1 CTNNA1 CTNNB1 ERBB2 ESR1 ESR2
12	nervous system	MP:0003631	9.8	CASK CTNNA1 CTNNB1 ERBB2 ESR1 ESR2
13	reproductive system	MP:0005389	9.76	CASK CDH1 CTNNB1 ERBB2 ESR1 ESR2
14	respiratory system	MP:0005388	9.35	CASK CTNNB1 ERBB2 ESR1 ESR2
15	skeleton	MP:0005390	9.17	CASK CTNNA1 CTNNB1 ERBB2 ESR1 ESR2

Sources

Drugs & Therapeutics for Lobular Neoplasia

Drugs for Lobular Neoplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Docetaxel

Approved, Investigational

Phase 4,Phase 2,Phase 3

114977-28-5

148124

Epirubicin

Approved

Phase 4,Phase 3,Phase 2

56420-45-2

41867

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2

6055-19-2, 50-18-0

2907

Antibiotics, Antitubercular

Phase 4,Phase 3,Phase 2

Antineoplastic Agents, Alkylating

Phase 4,Phase 3,Phase 2

Immunologic Factors

Phase 4,Phase 3,Phase 2

Antimitotic Agents

Phase 4,Phase 3,Phase 2

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 2

Alkylating Agents

Phase 4,Phase 3,Phase 2

Antirheumatic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2

Topoisomerase Inhibitors

Phase 4,Phase 3,Phase 2

Capecitabine

Approved, Investigational

Phase 2, Phase 3

154361-50-9

60953

Trastuzumab

Approved, Investigational

Phase 2, Phase 3,Phase 3

180288-69-1

9903

Medroxyprogesterone acetate

Approved, Investigational

Phase 3

71-58-9

Tamoxifen

Approved

Phase 3,Phase 2,Not Applicable

10540-29-1

2733526

Sodium Citrate

Approved, Investigational

Phase 3,Phase 2,Not Applicable

68-04-2

Doxorubicin

Approved, Investigational

Phase 3,Phase 2

23214-92-8

31703

Fluorouracil

Approved

Phase 3,Phase 2

51-21-8

3385

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2

33069-62-4

36314

Exemestane

Approved, Investigational

Phase 3

107868-30-4

60198

Letrozole

Approved, Investigational

Phase 3,Phase 1

112809-51-5

3902

Anastrozole

Approved, Investigational

Phase 3

120511-73-1

2187

Progesterone

Approved, Vet_approved

Phase 3,Not Applicable

57-83-0

5994

Metformin

Approved

Phase 3

657-24-9

14219 4091

Triamcinolone

Approved, Vet_approved

Phase 3

124-94-7

31307

Oxybutynin

Approved, Investigational

Phase 3

5633-20-5

4634

Pertuzumab

Approved

Phase 3

380610-27-5, 145040-37-5

2540

Carboplatin

Approved

Phase 3

41575-94-4

38904 10339178 498142

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Not Applicable

77-92-9

311

Doxil

Approved June 1999

Phase 3,Phase 2

31703

Lapatinib

Approved March 2007, Investigational

Phase 3,Phase 2

388082-78-8, 231277-92-2

208908 9941095

Antimetabolites, Antineoplastic

Phase 3,Phase 2

Antimetabolites

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2

Antineoplastic Agents, Immunological

Phase 2, Phase 3,Phase 3

Contraceptive Agents

Phase 3

Hormone Antagonists

Phase 3,Phase 2,Phase 1,Not Applicable

Selective Estrogen Receptor Modulators

Phase 3,Phase 2,Not Applicable

Estrogens

Phase 3,Phase 2,Phase 1,Not Applicable

Citrate

Phase 3,Phase 2,Not Applicable

Medroxyprogesterone

Phase 3

520-85-4

10631

Antineoplastic Agents, Hormonal

Phase 3,Phase 2,Not Applicable

Hormones

Phase 3,Phase 2,Phase 1,Not Applicable

Bone Density Conservation Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Estrogen Receptor Modulators

Phase 3,Phase 2,Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 3,Phase 2,Phase 1,Not Applicable

Estrogen Receptor Antagonists

Phase 3,Phase 2,Phase 1,Not Applicable

Estrogen Antagonists

Phase 3,Phase 2,Phase 1,Not Applicable

Contraceptives, Oral

Phase 3

Interventional clinical trials:

(show top 50) (show all 69)

#	Name	Status	NCT ID	Phase	Drugs
1	Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery	Recruiting	NCT02627248	Phase 4	Huaier Granule;Epirubicin;Docetaxel;Cyclophosphamide
2	S9630, Medroxyprogesterone in Treating Women With Breast Cancer	Completed	NCT00002920	Phase 3	medroxyprogesterone;tamoxifen citrate
3	Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer	Completed	NCT00336791	Phase 3	5-Fluorouracil;Cyclophosphamide;Doxorubicin;Paclitaxel;Epirubicin
4	Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer	Completed	NCT00374322	Phase 3	lapatinib
5	Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer	Completed	NCT00083174	Phase 3	exemestane
6	Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer	Completed	NCT00004205	Phase 3	letrozole;tamoxifen citrate
7	Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women	Completed	NCT00003906	Phase 3	Raloxifene;Tamoxifen
8	Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy	Completed	NCT00053898	Phase 3	anastrozole;tamoxifen citrate
9	A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin	Recruiting	NCT03085368	Phase 2, Phase 3	lapatinib/herceptin
10	Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer	Recruiting	NCT01905046	Phase 3	metformin hydrochloride
11	Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia	Active, not recruiting	NCT01357772	Phase 3	Tamoxifen;placebo
12	Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer	Active, not recruiting	NCT01547741	Phase 3	Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
13	Oxybutynin Chloride in Managing Hot Flashes	Active, not recruiting	NCT02961790	Phase 3	Oxybutynin Chloride
14	A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer	Active, not recruiting	NCT01358877	Phase 3	5-Fluorouracil;Carboplatin;Cyclophosphamide;Docetaxel;Doxorubicin;Epirubicin;Paclitaxel;Pertuzumab;Placebo;Trastuzumab
15	The LightPath® and 68Ga-RM2 in Breast Cancer Study	Not yet recruiting	NCT03731026	Phase 3	68Ga-RM2
16	"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"	Unknown status	NCT01641406	Phase 2	Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
17	Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors	Unknown status	NCT01849250	Phase 2	Docosahexaenoic Acid
18	Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.	Completed	NCT00524303	Phase 2	Trastuzumab;Paclitaxel;FEC75;Lapatinib
19	Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer	Completed	NCT01869764	Phase 2
20	Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease	Completed	NCT00031720	Phase 2	Tamoxifen
21	A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.	Completed	NCT00717405	Phase 2	Standard chemotherapy;bevacizumab [Avastin];trastuzumab [Herceptin]
22	Ruxolitinib for Premalignant Breast Disease	Recruiting	NCT02928978	Phase 2	Ruxolitinib;Placebo (for Ruxolitinib)
23	Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer	Active, not recruiting	NCT02137252	Phase 2	Naltrexone;Sugar Pill
24	Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer	Active, not recruiting	NCT01556243	Phase 2
25	Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy	Active, not recruiting	NCT02314156	Phase 2	Telapristone Acetate;Telapristone Acetate
26	3D-CRT, Proton, or Brachytherapy APBI in Treating Patients With Invasive and Non-invasive Breast Cancer	Active, not recruiting	NCT03391388	Phase 2
27	Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery	Active, not recruiting	NCT01082211	Phase 2
28	Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery	Active, not recruiting	NCT00436566	Phase 2	cyclophosphamide;doxorubicin hydrochloride;lapatinib ditosylate;paclitaxel
29	Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer	Terminated	NCT00096369	Phase 2	tamoxifen citrate
30	S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women	Terminated	NCT00088972	Phase 2	celecoxib
31	Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery	Terminated	NCT01754519	Phase 2
32	Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial	Completed	NCT01372644	Phase 1	SOM 230 / Pasireotide
33	Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer	Completed	NCT01077453	Phase 1	letrozole
34	A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer	Completed	NCT00637481	Phase 1	atorvastatin calcium
35	Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer	Completed	NCT00245024	Phase 1	sulindac
36	Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer	Recruiting	NCT03323658	Phase 1	Bexarotene
37	Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery	Suspended	NCT03317405	Phase 1	Z-Endoxifen Hydrochloride
38	Genetics of Women With Lobular Carcinoma in Situ of the Breast	Unknown status	NCT00536718
39	Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy	Completed	NCT00146536
40	Molecular Breast Imaging in Women With Atypia and LCIS	Completed	NCT00620087	Not Applicable
41	Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast	Completed	NCT01841749	Not Applicable
42	S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer	Completed	NCT01097278	Not Applicable
43	Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer	Completed	NCT01874184	Not Applicable
44	Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer	Completed	NCT00666731
45	Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer	Completed	NCT01293032	Not Applicable	Systemic Chemotherapy;Tamoxifen Citrate;Aromatase Inhibition Therapy
46	Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients	Completed	NCT01723943	Not Applicable
47	Three Different Programs of Paced Breathing in Treating Hot Flashes in Women	Completed	NCT00569166	Not Applicable
48	Study of Barriers to Beginning and Finishing Treatment for Patients With Breast Cancer	Completed	NCT00937989	Not Applicable
49	Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer	Completed	NCT00084669	Not Applicable	venlafaxine;zolpidem tartrate
50	High-Risk Breast Duct Epithelium	Recruiting	NCT00028340

Search NIH Clinical Center for Lobular Neoplasia

Sources

Genetic Tests for Lobular Neoplasia

Sources

Anatomical Context for Lobular Neoplasia

MalaCards organs/tissues related to Lobular Neoplasia:

⁴²

Breast, Bone

Sources

Publications for Lobular Neoplasia

Articles related to Lobular Neoplasia:

(show top 50) (show all 93)

#	Title	Authors	Year
1	Supplemental ultrasound screening in patients with a history of lobular neoplasia. ( 30675929 )	Phalak KA...Dogan BE	2019
2	Observation versus excision of lobular neoplasia on core needle biopsy of the breast. ( 29299726 )	Schmidt H....Jaffer S.	2018
3	Sonographic Appearance of Lesions Diagnosed as Lobular Neoplasia at Sonographically Guided Biopsies. ( 28075608 )	FerrAc R....Mesurolle B.	2017
4	Is the outcome at surgery different when flat epithelial atypia and lobular neoplasia are found in association at biopsy? ( 28118035 )	El Khoury M....Mesurolle B.	2017
5	Lobular Neoplasia and Atypical Ductal Hyperplasia on Core Biopsy: Current Surgical Management Recommendations. ( 28766203 )	Racz J.M....Degnim A.C.	2017
6	Lobular neoplasia diagnosed on breast Core biopsy: frequency of carcinoma on excision and implications for management. ( 27806840 )	Calhoun B.C....Downs-Kelly E.	2016
7	When pathological and radiological correlation is achieved, excision of fibroadenoma with lobular neoplasia on core biopsy is not warranted. ( 27718416 )	Fives C....Browne T.J.	2016
8	Lobular Neoplasia: Another Reset in Management? ( 26676981 )	Dunderdale J....Khan S.A.	2016
9	Surgical Outcomes of Lobular Neoplasia Diagnosed in Core Biopsy: Prospective Study ofA 316 Cases. ( 27425222 )	Susnik B....Lillemoe T.J.	2016
10	Lobular neoplasia detected in MRI-guided core biopsy carries a high risk for upgrade: a study of 63 cases from four different institutions. ( 26564004 )	Khoury T....Reig B.	2016
11	The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane Project. ( 27060553 )	Maxwell A.J....Thompson A.	2016
12	CD10-positive myoepithelial cells are usually prominent around in situ lobular neoplasia of the breast and much less prominent or absent in DCIS. ( 26862059 )	Shousha S....Wright J.A.	2016
13	Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020). ( 26542585 )	Nakhlis F....King T.A.	2015
14	Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. ( 24441664 )	Wells J.M....Shin S.J.	2014
15	Lobular neoplasia: morphology and management. ( 25268198 )	Jorns J....Pang J.C.	2014
16	Mucinous breast carcinoma with a lobular neoplasia component: a subset with aberrant expression of cell adhesion and polarity molecules and lack of neuroendocrine differentiation. ( 24888775 )	Jimbo K....Kinoshita T.	2014
17	Lobular neoplasia. ( 24882347 )	King T.A....Reis-Filho J.S.	2014
18	Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast. ( 24948027 )	Gomes D.S....Gobbi H.	2014
19	Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods. ( 24633840 )	Oliveira T.M....Muglia V.	2014
20	Lobular neoplasia: what does it mean and how should it be treated? ( 23617527 )	Hall F.M.	2013
21	Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. ( 23759937 )	Dabbs D.J....Reis-Filho J.S.	2013
22	Classic lobular neoplasia on core biopsy: a clinical and radio-pathologic correlation study with follow-up excision biopsy. ( 23307062 )	Chaudhary S....Bhuiya T.	2013
23	Low frequency of cancer occurrence in same breast quadrant diagnosed with lobular neoplasia at percutaneous needle biopsy. ( 22344406 )	Provencher L....Diorio C.	2012
24	Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. ( 21953071 )	Giricz O....Loudig O.	2012
25	Cadherin-catenin complex dissociation in lobular neoplasia of the breast. ( 22080244 )	Morrogh M....King T.A.	2012
26	Lobular lesions of the breast: imaging findings of lobular neoplasia and invasive lobular carcinoma. ( 22324264 )	Choi B.B....Shu K.S.	2012
27	Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. ( 22847124 )	Shah-Khan M.G....Glazebrook K.N.	2012
28	Is excisional biopsy required after a breast core biopsy yields lobular neoplasia? ( 22997389 )	Niell B....Rafferty E.	2012
29	Pathologic findings of follow-up surgical excision for lobular neoplasia on breast core biopsy performed for calcification. ( 22706860 )	Zhao C....Dabbs D.	2012
30	Breast-specific gamma imaging in the detection of atypical ductal hyperplasia and lobular neoplasia. ( 22578225 )	Ling C.M....Brem R.F.	2012
31	Surgical outcome of biopsy-proven lobular neoplasia: is there any difference between lobular carcinoma in situ and atypical lobular hyperplasia? ( 22268170 )	Ibrahim N....El-Khoury M.	2012
32	Lobular neoplasia: frequency and association with other breast lesions. ( 21827679 )	Gomes D.S....Gobbi H.	2011
33	Amplification of the prolactin receptor gene in mammary lobular neoplasia. ( 20658264 )	Tran-Thanh D....Done S.J.	2011
34	In situ lobular neoplasia of the breast with marked myoepithelial proliferation. ( 21707709 )	Shousha S.	2011
35	Lobular neoplasia found on breast biopsy: marker of increased risk of malignancy or direct pre-cancerous lesion? ( 22038220 )	Szynglarewicz B....Kornafel J.	2011
36	Lobular neoplasia: how to manage with partial understanding. ( 22106558 )	Visscher D.W....Hartmann L.C.	2011
37	Management of in situ lobular neoplasia detected on needle core biopsy of breast. ( 20972243 )	Purdie C.A....Jordan L.B.	2010
38	Lobular neoplasia: morphology, biological potential and management in core biopsies. ( 20436498 )	O'Malley F.P.	2010
39	Lobular neoplasia displaying central necrosis: a potential diagnostic pitfall. ( 20359832 )	Rosa M....Masood S.	2010
40	Lobular neoplasia of the breast. ( 20701604 )	Venkitaraman R.	2010
41	Lobular neoplasia: evolution of its significance and morphologic spectrum. ( 20484286 )	Tavassoli F.A.	2010
42	Lobular neoplasia of the breast: 68 years on. ( 19089737 )	Ho B.C....Tan P.H.	2009
43	Lobular neoplasia of the breast: an update. ( 19642738 )	Contreras A....Sattar H.	2009
44	Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. ( 19294736 )	Zou D....Humar B.	2009
45	Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. ( 19170233 )	Rudloff U....Van Zee K.J.	2009
46	Is excisional biopsy indicated for patients with lobular neoplasia diagnosed on percutaneous core needle biopsy of the breast? ( 19969131 )	Mulheron B....Apsey H.	2009
47	Sampling lobular neoplasia of the breast: underestimation despite technical success? ( 19466452 )	Zagouri F....Zografos G.C.	2009
48	Lobular neoplasia: core needle breast biopsy underestimation of malignancy in relation to radiologic and pathologic features. ( 18619840 )	Londero V....Bazzocchi M.	2008
49	In situ and invasive lobular neoplasia of the breast. ( 18171417 )	Hanby A.M....Hughes T.A.	2008
50	Lobular neoplasia at percutaneous breast biopsy: variables associated with carcinoma at surgical excision. ( 18287433 )	Brem R.F....Wasden S.	2008

Sources

Genes for Lobular Neoplasia

Genes related to Lobular Neoplasia (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CDH1	Cadherin 1	Protein Coding	24.51	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	ESR1	Estrogen Receptor 1	Protein Coding	22.61	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	ESR2	Estrogen Receptor 2	Protein Coding	21.35	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	CTNNB1	Catenin Beta 1	Protein Coding	21.11	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	PRLR	Prolactin Receptor	Protein Coding	20.59	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	HSP90AA1	Heat Shock Protein 90 Alpha Family Class A Member 1	Protein Coding	20.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	CTNNA1	Catenin Alpha 1	Protein Coding	16.71	GeneCards inferred via : Publications (show sections)
8	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	16.71	GeneCards inferred via : Publications (show sections)
9	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	16.13	DISEASES inferred ¹⁵
10	CASK	Calcium/Calmodulin Dependent Serine Protein Kinase	Protein Coding	15.77	DISEASES inferred ¹⁵

Sources

Variations for Lobular Neoplasia

Cosmic variations for Lobular Neoplasia:

⁹ (show top 50) (show all 1435)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location
1	COSM6949530	ZRSR2	breast,NS,carcinoma,lobular carcinoma	c.772-1G>C	p.?	23:15818586-15818586
2	COSM6958693	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.7262C>G	p.S2421*	16:72795420-72795420
3	COSM5037959	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.4556C>G	p.S1519*	16:72798126-72798126
4	COSM6953298	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.9220C>T	p.Q3074*	16:72793462-72793462
5	COSM6906826	YES1	breast,NS,carcinoma,lobular carcinoma	c.1090G>C	p.D364H	18:739782-739782
6	COSM6921648	YAP1	breast,NS,carcinoma,lobular carcinoma	c.952C>T	p.Q318*	11:102223703-102223703
7	COSM3839782	XPO1	breast,NS,carcinoma,lobular carcinoma	c.1160C>G	p.S387C	2:61493979-61493979
8	COSM6923776	XPO1	breast,NS,carcinoma,lobular carcinoma	c.2260G>T	p.E754*	2:61488218-61488218
9	COSM6953971	XIAP	breast,NS,carcinoma,lobular carcinoma	c.1240C>G	p.L414V	23:123900633-123900633
10	COSM638	WNK1	breast,NS,carcinoma,lobular carcinoma	c.1255G>C	p.E419Q	12:830104-830104
11	COSM637	WNK1	breast,NS,carcinoma,lobular carcinoma	c.6569C>G	p.S2190C	12:900596-900596
12	COSM18026	VHL	breast,NS,carcinoma,lobular carcinoma	c.562C>G	p.L188V	3:10149885-10149885
13	COSM17721	VHL	breast,NS,carcinoma,lobular carcinoma	c.241C>T	p.P81S	3:10142088-10142088
14	COSM51319	USP28	breast,NS,carcinoma,lobular carcinoma	c.2050G>A	p.D684N	11:113809177-113809177
15	COSM6963846	TSHR	breast,NS,carcinoma,lobular carcinoma	c.1283C>T	p.A428V	14:81143341-81143341
16	COSM6911141	TSC2	breast,NS,carcinoma,lobular carcinoma	c.700G>A	p.E234K	16:2056695-2056695
17	COSM6929739	TSC2	breast,NS,carcinoma,lobular carcinoma	c.3042C>G	p.S1014R	16:2079107-2079107
18	COSM6909235	TSC2	breast,NS,carcinoma,lobular carcinoma	c.1615C>T	p.L539F	16:2065534-2065534
19	COSM6971312	TSC2	breast,NS,carcinoma,lobular carcinoma	c.429C>G	p.F143L	16:2054388-2054388
20	COSM6958690	TSC2	breast,NS,carcinoma,lobular carcinoma	c.3887C>G	p.S1296C	16:2083698-2083698
21	COSM6971309	TSC1	breast,NS,carcinoma,lobular carcinoma	c.3208G>A	p.A1070T	9:132896522-132896522
22	COSM6188	TRIM33	breast,NS,carcinoma,lobular carcinoma	c.2968-1G>C	p.?	1:114399610-114399610
23	COSM6971833	TRAF7	breast,NS,carcinoma,lobular carcinoma	c.104G>A	p.G35E	16:2165901-2165901
24	COSM3408510	TP63	breast,NS,carcinoma,lobular carcinoma	c.679G>A	p.A227T	3:189864331-189864331
25	COSM6940226	TP63	breast,NS,carcinoma,lobular carcinoma	c.1865G>T	p.S622I	3:189894324-189894324
26	COSM6958680	TP63	breast,NS,carcinoma,lobular carcinoma	c.1079G>C	p.R360T	3:189868666-189868666
27	COSM6926297	TP63	breast,NS,carcinoma,lobular carcinoma	c.1432G>C	p.V478L	3:189886476-189886476
28	COSM10768	TP53	breast,NS,carcinoma,lobular carcinoma	c.535C>T	p.H179Y	17:7675077-7675077
29	COSM43878	TP53	breast,NS,carcinoma,lobular carcinoma	c.427G>A	p.V143M	17:7675185-7675185
30	COSM43606	TP53	breast,NS,carcinoma,lobular carcinoma	c.734G>A	p.G245D	17:7674229-7674229
31	COSM10656	TP53	breast,NS,carcinoma,lobular carcinoma	c.742C>T	p.R248W	17:7674221-7674221
32	COSM10812	TP53	breast,NS,carcinoma,lobular carcinoma	c.722C>T	p.S241F	17:7674241-7674241
33	COSM44599	TP53	breast,NS,carcinoma,lobular carcinoma	c.587G>A	p.R196Q	17:7674944-7674944
34	COSM10719	TP53	breast,NS,carcinoma,lobular carcinoma	c.811G>A	p.E271K	17:7673809-7673809
35	COSM10733	TP53	breast,NS,carcinoma,lobular carcinoma	c.574C>T	p.Q192*	17:7674957-7674957
36	COSM11073	TP53	breast,NS,carcinoma,lobular carcinoma	c.1024C>T	p.R342*	17:7670685-7670685
37	COSM44169	TP53	breast,NS,carcinoma,lobular carcinoma	c.614A>C	p.Y205S	17:7674917-7674917
38	COSM43695	TP53	breast,NS,carcinoma,lobular carcinoma	c.748C>T	p.P250S	17:7674215-7674215
39	COSM11552	TP53	breast,NS,carcinoma,lobular carcinoma	c.775G>T	p.D259Y	17:7674188-7674188
40	COSM44268	TP53	breast,NS,carcinoma,lobular carcinoma	c.559+1G>T	p.?	17:7675052-7675052
41	COSM10654	TP53	breast,NS,carcinoma,lobular carcinoma	c.637C>T	p.R213*	17:7674894-7674894
42	COSM10648	TP53	breast,NS,carcinoma,lobular carcinoma	c.524G>A	p.R175H	17:7675088-7675088
43	COSM46103	TP53	breast,NS,carcinoma,lobular carcinoma	c.319T>G	p.Y107D	17:7676050-7676050
44	COSM10722	TP53	breast,NS,carcinoma,lobular carcinoma	c.853G>A	p.E285K	17:7673767-7673767
45	COSM10728	TP53	breast,NS,carcinoma,lobular carcinoma	c.839G>A	p.R280K	17:7673781-7673781
46	COSM11059	TP53	breast,NS,carcinoma,lobular carcinoma	c.713G>A	p.C238Y	17:7674250-7674250
47	COSM10704	TP53	breast,NS,carcinoma,lobular carcinoma	c.844C>T	p.R282W	17:7673776-7673776
48	COSM10726	TP53	breast,NS,carcinoma,lobular carcinoma	c.856G>A	p.E286K	17:7673764-7673764
49	COSM10867	TP53	breast,NS,carcinoma,lobular carcinoma	c.797G>A	p.G266E	17:7673823-7673823
50	COSM43597	TP53	breast,NS,carcinoma,lobular carcinoma	c.538G>T	p.E180*	17:7675074-7675074

Sources

Expression for Lobular Neoplasia

Search GEO for disease gene expression data for Lobular Neoplasia.

Sources

Pathways for Lobular Neoplasia

Pathways related to Lobular Neoplasia according to GeneCards Suite gene sharing:

(show all 44)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁵ Show member pathways ILK Signaling ⁶⁵ MAPK Signaling ⁶⁵ Molecular Mechanisms of Cancer ⁶⁵ Rho Family GTPases ⁶⁵	13.63	CDH1 CTNNA1 CTNNB1 ERBB2 ESR1 ESR2
2	Nanog in Mammalian ESC Pluripotency ⁶⁵ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁵ eNOS Signaling ⁶⁵ GSK3 Signaling ⁶⁵	13.06	CDH1 CTNNB1 ERBB2 ESR1 ESR2 HSP90AA1
3	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	12.82	CTNNB1 ERBB2 HSP90AA1 PRLR
4	Sertoli-Sertoli Cell Junction Dynamics ⁶⁵ Show member pathways Epithelial Tight Junctions ⁶⁵ Germ Cell-Sertoli Cell Junction Dynamics ⁶⁵	12.75	CASK CDH1 CTNNA1 CTNNB1
5	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.65	CDH1 CTNNA1 CTNNB1 ERBB2 HSP90AA1
6	Cell junction organization ⁶⁷ Show member pathways Adherens junctions interactions ⁶⁷ Cell-Cell communication ⁶⁷ Cell-cell junction organization ⁶⁷ Cell-extracellular matrix interactions ⁶⁷ DSCAM interactions ⁶⁷ Localization of the PINCH-ILK-PARVIN complex to focal adhesions ⁶⁷ Nectin/Necl trans heterodimerization ⁶⁷ Regulation of cytoskeletal remodeling and cell spreading by IPP complex components ⁶⁷ Signal regulatory protein (SIRP) family interactions ⁶⁷ Tight junction interactions ⁶⁷ Type I hemidesmosome assembly ⁶⁷	12.5	CASK CDH1 CTNNA1 CTNNB1
7	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.49	CDH1 ERBB2 ESR1 ESR2
8	Development HGF signaling pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²³ Apoptosis and survival NGF signaling pathway ²³ Apoptosis and survival Role of CDK5 in neuronal death and survival ²³ Development Neurotrophin family signaling ²³ MET activates PTPN11 ⁶⁷ MET activates STAT3 ⁶⁷ Neurotrophin signaling pathway ³⁸ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.46	CDH1 CTNNA1 CTNNB1 ERBB2 ESR1
9	Prolactin Signaling Pathway ¹ ³⁸ Show member pathways Development Prolactin receptor signaling ²³ Leptin signaling pathway ¹	12.31	ERBB2 ESR1 ESR2 PRLR
10	Development VEGF signaling via VEGFR2 - generic cascades ²³ Show member pathways Development VEGF signaling and activation ²³ VEGF - VEGF R2 Signaling Pathways ⁶⁶	12.25	CTNNB1 ESR1 HSP90AA1
11	G-protein signaling RAC1 in cellular process ²³ Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²³ RAC1 signaling pathway ¹	12.21	CDH1 CTNNA1 CTNNB1 ERBB2
12	Development Ligand-independent activation of ESR1 and ESR2 ²³ Show member pathways Transcription CREB pathway ²³ Transcription PPAR Pathway ²³	12.17	ERBB2 ESR1 ESR2
13	Proteoglycans in cancer ³⁸	12.14	CTNNB1 ERBB2 ESR1
14	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	12.1	CDH1 CTNNA1 CTNNB1 ERBB2 ESR1 ESR2
15	CD28 co-stimulation ⁶⁷ Show member pathways Activation of AKT2 ⁶⁷ CD28 dependent PI3K/Akt signaling ⁶⁷ CD28 dependent Vav1 pathway ⁶⁷ Costimulation by the CD28 family ⁶⁷ VEGFR2 mediated vascular permeability ⁶⁷	12.05	CTNNA1 CTNNB1 HSP90AA1
16	Hippo signaling pathway ³⁸	12	CDH1 CTNNA1 CTNNB1
17	Integrated Breast Cancer Pathway ¹	11.99	CDH1 CTNNB1 ESR1
18	Presenilin-Mediated Signaling ⁶⁵	11.91	CDH1 CTNNA1 CTNNB1
19	Pathways in cancer ³⁸	11.89	CDH1 CTNNA1 CTNNB1 ERBB2 ESR1 ESR2
20	Remodeling of Adherens Junctions ⁶⁵	11.86	CDH1 CTNNA1 CTNNB1
21	Signaling by ERBB4 ⁶⁷ Show member pathways Downregulation of ERBB4 signaling ⁶⁷ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁷	11.78	ERBB2 ESR1 PRLR
22	Adhesion ⁴	11.71	CDH1 CTNNA1 CTNNB1 MUC1
23	Bacterial invasion of epithelial cells ³⁸	11.59	CDH1 CTNNA1 CTNNB1
24	Arf6 trafficking events ¹	11.31	CDH1 CTNNA1 CTNNB1
25	Adherens junction ³⁸	11.31	CDH1 CTNNA1 CTNNB1 ERBB2
26	Cell adhesion_Endothelial cell contacts by non-junctional mechanisms ²³	11.29	CTNNA1 CTNNB1
27	Cell adhesion_Cadherin-mediated cell adhesion ²³	11.26	CDH1 CTNNA1 CTNNB1
28	Stabilization and expansion of the E-cadherin adherens junction ¹	11.23	CDH1 CTNNA1 CTNNB1
29	Signaling events mediated by HDAC Class II ¹	11.22	ESR1 HSP90AA1
30	N-cadherin signaling events ¹	11.2	CTNNA1 CTNNB1
31	Cell adhesion_Endothelial cell contacts by junctional mechanisms ²³	11.18	CTNNA1 CTNNB1
32	Ovarian Infertility Genes ¹	11.18	ESR2 PRLR
33	a6b1 and a6b4 Integrin signaling ¹	11.16	CDH1 ERBB2
34	G-protein signaling_Rac2 regulation pathway ²³	11.16	CDH1 CTNNA1 CTNNB1
35	Extracellular vesicle-mediated signaling in recipient cells ¹	11.14	CTNNB1 ERBB2
36	Apoptosis and survival_Anti-apoptotic action of nuclear ESR1 and ESR2 ²³	11.1	ESR1 ESR2
37	E-cadherin signaling in the nascent adherens junction ¹	11.1	CDH1 CTNNA1 CTNNB1
38	Plasma membrane estrogen receptor signaling ¹	11.07	ESR1 ESR2
39	AHR Pathway ⁶⁵	11.04	ESR1 HSP90AA1
40	MNAR-PELP1 and Estrogen Receptor Interaction ⁶⁵	11	ESR1 ESR2
41	Nectin adhesion pathway ¹	10.94	CDH1 CTNNA1 CTNNB1
42	E-cadherin signaling in keratinocytes ¹	10.9	CDH1 CTNNA1
43	RHO GTPases activate IQGAPs ⁶⁷	10.55	CDH1 CTNNA1 CTNNB1
44	Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics ⁶²	10.13	ESR1 ESR2

Sources

GO Terms for Lobular Neoplasia

Cellular components related to Lobular Neoplasia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	plasma membrane	GO:0005886	9.81	CASK CDH1 CTNNA1 CTNNB1 ERBB2 ESR1
2	perinuclear region of cytoplasm	GO:0048471	9.78	CDH1 CTNNB1 ERBB2 HSP90AA1
3	actin cytoskeleton	GO:0015629	9.63	CASK CDH1 CTNNA1
4	basolateral plasma membrane	GO:0016323	9.61	CASK CTNNB1 ERBB2
5	lamellipodium	GO:0030027	9.58	CDH1 CTNNA1 CTNNB1
6	cell-cell junction	GO:0005911	9.54	CASK CTNNA1 CTNNB1
7	cell-cell adherens junction	GO:0005913	9.43	CDH1 CTNNA1 CTNNB1
8	apical junction complex	GO:0043296	9.32	CDH1 CTNNB1
9	catenin complex	GO:0016342	9.13	CDH1 CTNNA1 CTNNB1
10	flotillin complex	GO:0016600	8.8	CDH1 CTNNA1 CTNNB1

Biological processes related to Lobular Neoplasia according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription, DNA-templated	GO:0045893	9.8	CDH1 CTNNB1 ESR1 ESR2
2	cell adhesion	GO:0007155	9.78	CASK CDH1 CTNNA1 CTNNB1
3	negative regulation of apoptotic process	GO:0043066	9.61	CTNNA1 CTNNB1 PRLR
4	positive regulation of protein kinase B signaling	GO:0051897	9.54	ERBB2 ESR1 HSP90AA1
5	regulation of angiogenesis	GO:0045765	9.52	CTNNB1 ERBB2
6	positive regulation of telomerase activity	GO:0051973	9.51	CTNNB1 HSP90AA1
7	ERBB2 signaling pathway	GO:0038128	9.46	ERBB2 HSP90AA1
8	positive regulation of DNA-binding transcription factor activity	GO:0051091	9.43	CTNNB1 ESR1 ESR2
9	positive regulation of muscle cell differentiation	GO:0051149	9.4	CTNNA1 CTNNB1
10	intracellular estrogen receptor signaling pathway	GO:0030520	9.32	ESR1 ESR2
11	entry of bacterium into host cell	GO:0035635	9.16	CDH1 CTNNB1
12	adherens junction organization	GO:0034332	9.13	CDH1 CTNNA1 CTNNB1
13	cellular response to indole-3-methanol	GO:0071681	8.8	CDH1 CTNNA1 CTNNB1

Molecular functions related to Lobular Neoplasia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	estrogen receptor binding	GO:0030331	9.48	CTNNB1 ESR1
2	disordered domain specific binding	GO:0097718	9.46	CTNNB1 HSP90AA1
3	steroid binding	GO:0005496	9.43	ESR1 ESR2
4	beta-catenin binding	GO:0008013	9.43	CDH1 CTNNA1 ESR1
5	gamma-catenin binding	GO:0045295	9.37	CDH1 CTNNA1
6	nitric-oxide synthase regulator activity	GO:0030235	9.32	ESR1 HSP90AA1
7	estrogen receptor activity	GO:0030284	9.16	ESR1 ESR2
8	identical protein binding	GO:0042802	9.1	CDH1 CTNNA1 ERBB2 ESR1 ESR2 HSP90AA1
9	estrogen response element binding	GO:0034056	8.96	ESR1 ESR2
10	protein binding	GO:0005515	10.1	CASK CDH1 CTNNA1 CTNNB1 ERBB2 ESR1

Sources

Sources for Lobular Neoplasia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia